aTyr Pharma Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From aTyr Pharma Inc
Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.
Appointments: Oculis, PellePharm, Syntimmune, Sterna Biologicals, Proclara Biosciences, Denovo Biopharma and OrphoMed
The latest biopharma industry appointments include new CEOs at Oculis, PellePharm, Syntimmune and Sterna Biologicals and a new CFO at Oculis, as well as new CMOs at Proclara Biosciences, Denovo Biopharma and OrphoMed.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.
- Large Molecule
- Other Names / Subsidiaries
- Pangu BioPharma